Brief: In8bio Announces Positive Data In Early-Stage Trial Of Blood Cancer Treatment

IN8bio

12/12/2022 15:11

Dec 12 (Reuters) - IN8BIO, Inc.  INAB.O :
    * IN8BIO ANNOUNCES NEW DATA AT ASH SHOWING 100 PERCENT OF
COHORT 1
PATIENTS MAINTAINED DURABLE COMPLETE RESPONSE IN ONGOING PHASE 1
TRIAL OF INB-100
    * IN8BIO, INC. - RESULTS FROM FIRST COHORT OF PATIENTS WITH
HEMATOLOGICAL MALIGNANCIES SHOW PATIENTS REMAINED PROGRESSION
FREE
    * IN8BIO, INC. - INB-100 CONTINUES TO DEMONSTRATE A
MANAGEABLE
SAFETY PROFILE WITH NO DOSE-LIMITING TOXICITIES (DLTS) OBSERVED
TO DATE
    * IN8BIO, INC. - ENROLLMENT FOR COHORT 2 HAS BEEN INITIATED
WITH
ADDITIONAL CLINICAL UPDATES EXPECTED IN 2Q 2023

Source text for Eikon:  ID:nGNXQT0jR 
Further company coverage:  INAB.O 
 ((Reuters.Briefs@thomsonreuters.com;))